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Studies directed at vaccine development and mucosal immunity against Streptococcus pyogenes would benefit
from the availability of live attenuated strains. Our approach for production of candidate live attenuated
strains was to identify mutations that did not alter growth in vitro and did not alter the overall complement
of virulence factors produced but did result in reduced levels of expression of multiple secreted virulence
factors. A global reduction but not elimination of expression would likely lead to attenuation while maximizing
the number of antigenic targets available for stimulation of immunity. Adaptation of Tn5-based transposome
mutagenesis to S. pyogenes with initial screening for reduced expression of the SpeB protease resulted in
identification of mutations in gidA, which encodes an enzyme involved in tRNA modification. Reduced SpeB
expression was due to delayed onset of speB transcription resulting from reduced translation efficiency of the
message for RopB, a transcriptional activator. Overall, GidA mutants had a nearly normal global transcrip-
tion profile but expressed significantly reduced levels of multiple virulence factors due to impaired translation
efficiencies. A translation defect was supported by the observation that mutants lacking MnmE, which func-
tions in the same tRNA modification pathway as GidA, phenocopied GidA deficiency. The mutants stimulated
a cytokine response in cultured macrophages identical to that in the wild type, with the exception of reduced
levels of tumor necrosis factor alpha and interleukin-23. Significantly, GidA mutants were highly attenuated
in the murine ulcer model of soft tissue infection. These characteristics suggest that GidA pathway tRNA
modification mutants are attractive candidates for further evaluation as live attenuated strains.
Despite the exquisite sensitivity of Streptococcus pyogenes
(group A streptococcus) to penicillin, diseases caused by this
organism remain a major public health concern in both devel-
oped and developing countries (6). This pathogenic gram-pos-
itive bacterium is the causative agent of myriad diseases,
ranging from severe invasive diseases (cellulitis, necrotizing
faciitis), toxigenic diseases (scarlet fever, toxic shock syn-
drome), and sequlae (rheumatic heart disease, glomerulone-
phritis) to more self-limiting diseases, including pyoderma and
pharyngitis. A recent analysis of the prevalence of group A
streptococcal diseases indicated that the minimum global bur-
den is upwards of 18 million cases of severe disease, with 1.78
million new cases arising each year, resulting in at least 517,000
deaths (6). This degree of mortality places group A strepto-
cocci among the major human pathogens, exceeded only by
human immunodeficiency virus, Mycobacterium tuberculosis,
Plasmodium falciparum, and Streptococcus pneumoniae (6).
While children in developing countries bear the greatest bur-
den of severe disease (40), the impact on the health care
system of the United States is also considerable, with cases of
acute pharyngitis accounting for as many as 11 million office
visits per year (3). The burden imposed by group A strepto-
cocci on the global population has stimulated considerable
interest in the development of new therapies for prevention of
these diseases.
A vaccination approach offers many advantages. However,
development of a safe and effective group A streptococcal
vaccine has met with several significant challenges. Among
these challenges are the fact that the pathogenesis of most
group A streptococcal diseases is not well understood and may
involve an autoimmune component in certain diseases, such as
rheumatic fever (11). Similarly, both the contribution of the
large number of secreted enzymes, toxins, and surface-associ-
ated factors produced by S. pyogenes to the pathogenesis of
specific diseases and the importance of the immune response
against these components to protective immunity are also not
well understood (11). Early studies established that serum im-
munoglobulin can be opsonic and can promote the neutrophil-
mediated killing of S. pyogenes in human blood (25). The an-
tibodies function by neutralizing the antiphagocytic property of
a streptococcal surface protein known as the M protein (for a
review, see reference 15), and the generation of these antibod-
ies has provided the rationale for several M protein-based
vaccine formulations (for a review, see reference 3). However,
several issues have complicated the development of vaccines
based on the M protein, including (i) the fact that there are
over 150 distinct serotypes of M protein and (ii) the fact that M
proteins can elicit the production of antibodies that are cross-
reactive with human tissues (10).
The use of peptides representing epitopes common to mul-
tiple serotypes, the use of multivalent peptides, and the use of
peptides that have been engineered to lack prominent cross-
reactive epitopes have all been used as strategies to increase
the safety and efficacy of M protein vaccines (3). However,
continuing concerns have stimulated investigation into other
* Corresponding author. Mailing address: Department of Molecular
Microbiology, Washington University School of Medicine, 660 S. Eu-
clid Ave., Box 8230, Saint Louis, MO 63110-1093. Phone: (314) 362-
1485. Fax: (314) 362-3203. E-mail: caparon@borcim.wustl.edu.
† Supplemental material for this article may be found at http://iai
.asm.org/.
‡ Present address: Department of Microbiology, Southern Illinois
University, Carbondale, IL 62901.





arch 18, 2014 by W







potential formulations, including the use of conserved surface
proteins (3), and have spurred several large-scale interroga-
tions of the surface proteome in the search for additional
vaccine candidates (34, 47, 51). A combination of these studies
with a thorough understanding of the immune response against
S. pyogenes would offer a more rationale approach to vaccine
design. Of particular utility would be a vaccine capable of
preventing S. pyogenes from colonizing the mucosal surfaces of
the nasopharynx, which is the primary site of most streptococ-
cus-host interactions (11). However, the factors that contribute
to immunity against S. pyogenes at a mucosal surface are not
well understood.
Effective immunity at a mucosal surface generally requires
engagement of the mucosal immune system, which is respon-
sible for the production of defense molecules, like secretory
immunoglobulin A, that are well adapted for defense in the
mucosal environment (31). Most mucosal vaccines in current
use accomplish this through the use of live attenuated strains
that can be administered by a route that mimics the natural
route of infection. The attenuated strains typically can undergo
the initial stages of pathogenesis but have mutations that re-
strict them to producing a self-limiting infection with minimal
symptomatology (12, 29). Unfortunately, there has been rela-
tively little work directed at the development of live attenuated
strains for analyses of immunity to S. pyogenes.
Since S. pyogenes pathogenesis is dependent upon secre-
tion of a large array of surface proteins, extracellular en-
zymes, and toxins (11), our approach to construction of a
candidate for a live attenuated strain was to conduct a
screen for a mutant with the following characteristics: (i) it
should have no obvious defect in growth characteristics in
vitro; (ii) it should have no obvious defect in the number of
different virulence factors that it expresses; and (iii) it
should have a measurable defect that causes it to produce a
large subset of its secreted virulence factors at significantly
reduced levels. We reasoned that a global reduction in, but
not elimination of, virulence factor expression would render
the mutant attenuated, while maximizing the repertory of
antigens that could be presented to the immune system. In
this report, we describe mutants defective in a tRNA mod-
ification pathway as candidates for such a live attenuated
strain. The pathway involves the proteins GidA and MnmE,
which is responsible for the addition of a carboxymethylami-
nomethyl group to uridine 34 of a subset of tRNAs that is
crucial for the appropriate decoding of many mRNAs (48).
While these mutants have no obvious in vitro growth defect
and a nearly normal global transcription profile, the level of
expression of multiple secreted virulence factors by them is
reduced but expression is not eliminated. In a subset of the
mutants, reduced expression results from a defect at the
level of translation of at least one key transcription regula-
tor. The mutants induce a nearly normal pattern of cytokine
expression in macrophages in vitro and are highly attenu-
ated in a murine ulcer model of soft tissue infection. The
fact that this pathway is highly conserved suggests that mu-
tation of the genes encoding the factors is a strategy that can
be applied to the construction of live attenuated strains of
other species of pathogenic streptococci.
MATERIALS AND METHODS
Bacterial strains. The bacterial strains and plasmids used in this study are
listed in Table 1. Molecular cloning experiments were performed with Esche-
richia coli DH5 which was cultured in Luria-Bertani broth (38) at 37°C. For
routine culture of S. pyogenes, Todd-Hewitt medium (BBL) supplemented with
0.2% yeast extract (Difco) (THY medium) was employed. Unless otherwise
indicated, for growth of S. pyogenes for SpeB activity assays, Western blot anal-
yses, and preparation of RNA for real-time reverse transcription (RT)-PCR C
medium was used (37). For growth in liquid media, S. pyogenes was cultured at
37°C in sealed tubes without agitation. To produce solid media, Bacto agar
(Difco) was added to a final concentration of 1.4% (wt/vol). When appropriate,
antibiotics were added to the media at the following concentrations: spectino-
mycin, 100 g/ml for E. coli and S. pyogenes; chloramphenicol, 15 g/ml for E.
coli and 3 g/ml for S. pyogenes; kanamycin, 50 g/ml for E. coli and 500 g/ml
for S. pyogenes; and erythromycin, 750 g/ml for E. coli and 1 g/ml for S.
pyogenes.
Manipulation and computational analyses of DNA. Plasmid DNA was isolated
via standard techniques and used to transform S. pyogenes as described previ-
ously (5). Restriction endonucleases, ligases, and polymerases were used accord-
ing to the manufacturer’s recommendations. The fidelity of all constructs derived
by PCR was confirmed by DNA sequencing analyses. All references to genomic
loci and predictions of protein function are based on the genome of S. pyogenes
strain SF370 (14) and were supported by interrogation of the nonrepetitive
sequence database at the National Center for Biotechnology Information (http:
//www.ncbi.nlm.nih.gov/BLAST/) using a gapped BLAST algorithm (2).
Construction of EZ-Tn5<Erm>. For application of Tn5-based “transpo-
some” mutagenesis (22) to S. pyogenes, the BamHI site of pMOD-2MCS
(Epicenter Biotechnologies) was used to insert a BamHI fragment that contains
the Erm element of pJDM-STM (30). The resulting plasmid was designated
pMOD-2::Tn5Erm, and the resulting transposable element was designated
EZ-Tn5Erm (Fig. 1A). The erythromycin resistance gene of the Erm
element can be used for selection in both E. coli and S. pyogenes (30).
Transposome mutagenesis. A gel-purified PvuI fragment of pMOD-2::Tn5
Erm that included Tn5Erm (Fig. 1A) was mixed in vitro with the
EZ-Tn5 transposase according to the directions of the manufacturer (Epicenter
Biotechnologies). Electroporation was then used to introduce the transposome
complex into competent cells of S. pyogenes that had been prepared by a standard
method (5) and then washed once at room temperature in a 15% (vol/vol)
glycerol solution containing 1 mM EDTA to remove Mg2. This additional step
was required for stabilization of the transposon-transposase complex prior to its
introduction into the streptococcal cell (22). Transformants with insertions of
Tn5Erm were then recovered following overnight incubation at 37°C on
THY medium plates supplemented with erythromycin. For mutants of interest,
the transposon insertion site was identified by direct sequencing of chromosomal
DNA using a transposon-specific primer (SqTM-r) (see Table S1 in the supple-
mental material) as described previously (18).
Directed mutagenesis and complementation. Insertional inactivation of spe-
cific genes and complementation analyses were conducted using a standard
recombinational strategy (8). For mutagenesis, an approximately 0.7-kbp frag-
ment of the gene of interest that lacked both its 5 and 3 ends was amplified by
PCR, inserted into pSPC18 (37), and then introduced into E. coli. The plasmid
was purified and then used to transform S. pyogenes. Since pSPC18 cannot
replicate in S. pyogenes, most transformants resistant to spectinomycin have
undergone a single homologous recombination event that results in disruption of
the targeted gene (8). For complementation of a GidA mutant, an intact copy
of gidA was introduced into the chromosome of the mutant as follows. A chro-
mosomal segment containing the entire predicted gidA open reading frame and
putative promoter region was amplified by PCR and inserted into the integra-
tional plasmid pCIV2 (34). Transformation followed by recombination of the
resulting plasmid into the mutant’s chromosome resulted in introduction of an
intact copy of gidA. Details for each integrating plasmid are shown in Table 1,
and the sequences of primers used for amplification of gene segments are shown
in Table S1 in the supplemental material. The chromosomal structure of each
mutant was confirmed by PCR using primers for the appropriate sequences. To
ensure that mutant phenotypes were specifically due to gene disruption and not
due to a nonspecific effect of integration of pSCP18 into the chromosome, a
strain with pSPC18 inserted into the intergenic region downstream of recF
(SPy_2204) (9), which is referred to here as HSC5spc (Table 1), was included in
selected analyses.
Analysis of protein expression. Analyses of cell growth and use of protease
indicator medium, Western blot analysis of SpeB secretion, and quantitative
measurement of SpeB activation and SpeB cysteine protease activity were all
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performed as described previously (37). Sample preparation and experiments
with antisera for Western blot analyses to quantitate expression of streptolysin O
(SLO), NAD glycohydrolase (SPN), mitogenic factor (MF), and RopA-hemag-
glutinin (RopA-HA) were conducted as described elsewhere (22, 35). Cells were
fractionated as described previously (36), and M protein in cell wall fractions was
analyzed by Western blotting using an antiserum developed against a peptide
(QELAKKEEQNKISDASRKG) that was shown to be involved in streptococcal
cell aggregation (16). The level of expression of a specific protein in various
mutants was expressed relative to its expression in the wild type by comparison
of band intensities in digital images of Western blots analyzed using IMAGEJ
software (1).
Analysis of transcription. RNA from the various streptococcal strains was
isolated and analyzed using real-time RT-PCR as described previously (27),
employing the primers listed in Table S1 in the supplemental material. Transcript
abundance was normalized to the results for recA, and the data presented below
are the means and standard deviations derived from at least two independent
experiments that were performed on different days, with each individual sample
analyzed in triplicate. Comparison of global transcriptional profiles using DNA
microarrays was conducted as described in detail elsewhere (6, 13, 36).
Infection of macrophages. Murine bone marrow-derived macrophages were
obtained by a standard procedure (7) and were cultured in RPMI 1640 contain-
ing L-glutamine (Cellgro Mediatech, Inc.) with 20% (vol/vol) heat-inactivated
fetal bovine serum (BioWhittaker, Inc.), 30% (vol/vol) L-cell conditioned me-
dium (a source of macrophage colony-stimulating factor), penicillin G (50 IU
ml1), and streptomycin (50 g ml1). Macrophages were cultured for 8 days,
harvested with ice-cold phosphate-buffered saline, resuspended in macrophage
medium (Dulbecco’s minimal essential medium [BioWhittaker, Inc.] containing
50 mM HEPES, 10% fetal bovine serum, and 8 mM L-glutamine), and then
plated at a density of 2.5 	 106 cells per well in a six-well plate (catalog no. 3506;
Corning Inc.). For infection, overnight cultures of S. pyogenes in THY medium
TABLE 1. Bacterial strains and plasmids
Strain(s) or plasmid Relevant characteristics Reference orsource





Transposon-generated gidA mutantsa This study
HSC5Spc Chromosomal insertion of pSPC18 downstream of recF in the HSC5 chromosome
without disruption of any gene or operon; previously referred to as “Control”
9
HSC5::pKHC100 HSC5 mutant with gidA disruption created with pKHC100b This study
HSC5::pKHC101 HSC5 mutant created with pKHC101; pSPC18 is inserted between gidA and
SPy_2184b
This study
HSC5::pKHC102 HSC5 mutant with SPy_2184 disruption created with pKHC102b This study
HSC5::pKHC100::pKHC103 Insertion of pKHC103 into HSC5::pKHC100; contains an intact gidA gene This study
HSC5::pKHC104 HSC5 mutant with mnmE disruption created with pKHC104 This study
HSC5::pKHC105 HSC5 mutant with SPy_1173 disruption created with pKHC105 This study
HSC5Spc(pRopB-HA) HSC5Spc transformed with pRopB-HA; produces RopB-HA This study
HSC5::pKHC100(pRopB-HA) HSC5::pKHC100 transformed with pRopB-HA; produces RopB-HA This study
HSC5::pKHC104(pRopB-HA) HSC5::pKHC104 transformed with pRopB-HA; produces RopB-HA This study
HSC5Spc(pSPN-HA) HSC5Spc transformed with pSPN-HA; produces SPN-HA This study
HSC5::pKHC100(pSPN-HA) HSC5::pKHC100 transformed with pSPN-HA; produces SPN-HA This study
HSC5::pKHC104(pSPN-HA) HSC5::pKHC104 transformed with pSPN-HA; produces SPN-HA This study
HSC5Spc(pMF-HA) HSC5spc transformed with pMF-HA; produces MF-HA This study
HSC5::pKHC100(pMF-HA) HSC5::pKHC100 transformed with pMF-HA; produces MF-HA This study
HSC5::pKHC104(pMF-HA) HSC5::pKHC104 transformed with pMF-HA; produces MF-HA This study
Plasmids
pMOD-2MCS pUC-based vector containing EZ-Tn5MCS Epicenter Inc.
pMOD-2::Tn5Erm pUC-based vector containing EZ-Tn5Erm; derived from pMOD-2MCSc This study
pSPC18 pUC18-based streptococcal integration vector; contains aad9 conferring
spectinomycin resistance
28
pCIV2 pUC18-based streptococcal integration vector; contains aphA3 conferring
kanamycin resistance
34
pSPC18::recF pSPC18 containing a 0.70-kbp C-terminal segment of recF 9
pKHC100 pSPC18 containing a 0.70-kbp internal fragment of gidA generated by PCR with
primers GidA-f and GidA-r
This study
pKHC101 pSPC18 containing a 0.62-kbp fragment spanning the gidA-SPy_2184 intergenic
region generated by PCR with primers Separate-f and Separate-r
This study
pKHC102 pSPC18 containing a 0.73-kbp internal fragment of SPy_2184 generated by PCR
with primers SPy2184-f and SPy2184-r
This study
pKHC103 pCIV2 containing a 2.43-kbp DNA fragment including gidA generated by PCR
with primers GidACisComp-f and GidACisComp-r
This study
pKHC104 pSPC18 containing 0.52-kbp internal fragment of mnmE generated by PCR with
primers MnmE-f and MnmE-r
This study
pKHC105 pSPC18 containing 0.58-kbp internal fragment of SPy_1173 generated by PCR
with primers SPy1173-f and SPy1173-r
This study
pRopB-HA pABG5 derivative containing HA-tagged ropB 26
pSPN-HA pABG5 derivative containing HA-tagged spn; same as pJOY7 17
pMF-HA pABG5 derivative containing HA-tagged mf; same as pJOY2 17
a For detailed information, see Fig. 1.
b See Fig. 2.
c See Fig. 1.
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were harvested, washed twice with phosphate-buffered saline, and then resus-
pended in macrophage medium to an optical density at 600 nm of 0.76. Portions
of this suspension ranging from 50 to 100 l were then added directly to wells
containing macrophages. Final multiplicities of infection were determined by
plating the streptococcal suspensions on THY agar following brief sonication to
disrupt the streptococcal chains. In selected experiments, streptococci were in-
activated by exposure to UV light (254 nm, 500 mJ/cm2) prior to incubation with
macrophages. This dose exceeds the lethal dose for S. pyogenes (44), which was
routinely confirmed by plating on THY agar.
Cytokine assays. Following 4 h of infection of macrophage cultures, the su-
pernatant fluids were harvested and then sterilized by filtration (Millex-GP; 0.22
m; Millipore Corp). Cytokine levels in these fluids were determined using a
commercial antibody-based multiplex bead assay (Bio-Plex, Mouse Cytokine
23-Plex; catalog no. 171-F11241; Bio-Rad Laboratories) to measure the 23 dif-
ferent murine cytokines that are listed in Fig. 8 and Fig. S2 in the supplemental
material. For this analysis the directions of the manufacturer (Bio-Rad Labora-
tories) were followed, and the analysis was conducted by the High Speed Cell
Sorter Core Lab at the Siteman Cancer Center of Washington University. The
data presented are the means and standard errors derived from three different
infections, which were conducted on different days, and each experiment was
analyzed in duplicate. Any differences in the mean values for specific cytokines
induced in response to mutants compared with the wild type were tested for
significance by the unpaired t test (19), and the null hypothesis was rejected when
the P value was 0.05.
Murine subcutaneous infection model. The abilities of selected mutants to
cause disease in soft tissue were evaluated by subcutaneous infection of 6- to
8-week-old SKH1 hairless mice (Charles River Labs) as described previously (4).
Various strains were analyzed using groups containing five mice, and each ex-
periment was repeated at least twice on different days. The area of the draining
ulcers that formed was documented every 24 h by digital photography, and the
precise area for each ulcer was calculated from the digital record using Meta-
Morph image analysis software (version 4.6; Universal Imaging Corp.). Any
differences in the areas of ulcers between experimental groups was tested for
significance by the Mann-Whitney U test (19), and the null hypothesis was
rejected when the P value was 0.05.
Microarray data accession number. The microarray data have been deposited
in the National Center for Biotechnology Information Gene Expression Omni-
bus (http://www.ncbi.nlm.nih.gov/geo) under GEO Series accession number
GSE9678.
RESULTS
Transposome mutagenesis identified the gidA gene. We
adapted a Tn5-based transposome mutagenesis strategy to
screen for a mutant with reduced virulence factor expression
(see Materials and Methods). This method has the advantages
that it is simple, target site selection is random, and, because
the inserted element itself does not encode transposase, inser-
tions are stable in the absence of continued antibiotic selection
(22). Introduction of a transposome complex generated with
EZ-Tn5Erm (Fig. 1A) into S. pyogenes HSC5 produced
transformants at an efficiency between 103 and104 CFU/g
DNA. An insertion library was then examined for mutants that
displayed reduced activity of the secreted SpeB cysteine pro-
tease following overnight culture on a protease indicator me-
dium (see Materials and Methods). Approximately 4,000 col-
onies were examined, and nine mutants with reduced activity
were identified that were subsequently found to express cys-
teine protease activity at levels between 5 and 20% of the
wild-type level when they were examined using a quantitative
proteolysis assay with a casein substrate (see Materials and
Methods) following growth in two different media (THY and C
media). Identification of the transposon insertion loci (see
Materials and Methods) revealed that six mutants had inser-
tions in the gene encoding RopB, which is a positive transcrip-
tional regulator of SpeB, and three mutants had insertions at
different sites within the gidA open reading frame (SPy_2185)
(Fig. 1B), whose orthologous gene products have been impli-
cated in the flavin adenine dinucleotide (FAD)-dependent
modification of tRNAs decoding two-family box triplet codons
(47). Mutation of gidA in E. coli causes cell elongation and slow
growth in rich media supplemented with glucose (45). How-
ever, the S. pyogenes mutants did not exhibit any measurable
defect in either the growth rate or cell morphology upon cul-
ture in several rich media (THY and C media) in the absence
or presence of additional glucose (0.5%, wt/vol) (data not
shown). Also, like the genomes of many bacterial species (46),
the S. pyogenes genome encodes a protein that is highly
homologous to, although somewhat smaller than, GidA
(SPy_1173) (20.1% identical and 55.1% similar). Insertional
inactivation of SPy_1173 did not lead to any observable defect
in SpeB biogenesis (data not shown).
Characterization of the gidA chromosomal region. Exami-
nation of the genomic data available for multiple S. pyogenes
strains revealed that the structure of the gidA chromosomal
region is strongly conserved and that this region includes genes
whose products are implicated in the function of ribosomes or
DNA polymerase or have an unknown function (Fig. 1B), all of
which may contribute to the biogenesis of SpeB and other
FIG. 1. (A) Transposable element EZ-Tn5Erm. The struc-
ture of the EZ-Tn5Erm transposon developed for transposome
mutagenesis (22) is shown. The Erm element contains an erythro-
mycin resistance determinant (erm) that is flanked by strong transcrip-
tion and translation terminators (indicated by “”) (30). The Erm
element is flanked by the left and right mosaic ends of Tn5 (arrow-
heads MEL and MER). For clarity, only a limited region of plasmid
pMOD-2::Tn5Erm (dashed line), a derivative of pMOD-2
MCS (Epicenter Biotechnologies), is shown. Restriction sites: Pv,
PvuI; B, BamHI. (B) Reduced SpeB expression as a result of transpo-
son insertion in gidA. The organization of the chromosomal region
containing gidA is shown at the top. The arrows indicate individual
open reading frames and their orientations and are labeled based on
the annotation of the S. pyogenes SF370 genome (14). The predicted
proteins encoded by these open reading frames and their putative
functions are shown at the bottom. The markers above gidA indicate
the sites of EZ-Tn5Erm insertion in three mutants (TM-GidA1
to TM-GidA3) that resulted in reduced expression of the SpeB cys-
teine protease. The specific sites of transposon insertion are as follows:
TM-GidA1, within a lysine codon (L368); TM-GidA2, following an
alanine codon (A16); and TM-GidA3, within a serine codon (S179).
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virulence factors. Since the EZ::Tn5Erm element in-
cludes strong transcription and translation terminators to en-
sure generation of strongly polar insertions (Fig. 1A), it was
necessary to examine the contribution of the adjacent genes to
the GidA phenotype. Insertion duplication mutations con-
structed to inactivate gidA and the open reading frame imme-
diately downstream (SPy_2184) (Fig. 2) produced two mutants
that both had reduced expression of SpeB (HSC5::pKHC100
and HSC5::pKHC102) (Fig. 2). However, when the amounts of
SpeB protein that were secreted into the supernatant were
compared using a Western blot analysis, the two mutants had
distinct phenotypes. When tested after 10 h of culture, the
GidA mutant secreted a reduced amount of SpeB protein,
like the original transposon insertion mutants. In contrast, the
SPy_2184 mutant secreted wild-type levels of the protease zy-
mogen at this time point but failed to process the inactive
precursor to the active protease (data not shown). A compar-
ison of the transcript levels of the genes downstream of gidA
(SPy_2184 and rplI) (Fig. 1B) between the wild type and a
transposon insertion mutant (TM-GidA1) (Fig. 1B) revealed
no significant differences when a real-time RT-PCR was used
(GidA mutant/wild-type strain expression ratio for SPy_2184,
0.92 
 0.17; GidA mutant/wild-type strain expression ratio
for rplI, 0.91 
 0.30), showing that insertions into gidA are not
polar for expression of downstream genes. Taken together,
these data suggested that both GidA and SPy_2184 are re-
quired for SpeB biogenesis but contribute to different steps. A
requirement for both genes was confirmed by construction of
an additional insertion duplication mutation that placed the
integrated plasmid between the intact gidA and SPy_2184 open
reading frames. The resulting strain (HSC5::pKHC101) (Fig.
2) expressed nearly wild-type levels of SpeB proteolytic activ-
ity. Finally, reintroduction of an intact copy of gidA into the
chromosome of a GidA mutant (see Materials and Methods)
resulted in a complemented strain whose protease activity
more closely resembled that of the wild type than that of the
GidA mutant on protease indicator plates (Fig. 3A) and
which produced SpeB activity in culture supernatants at nearly
wild-type levels (Fig. 3B). Based on these data, we concluded
that the reduced-expression phenotype observed in the trans-
poson insertion mutants was due to the loss of gidA.
Transcription of speB is delayed in GidA mutants. Expres-
sion of speB is known to be highly regulated at the level of
transcription, and this gene is expressed in a growth phase-
dependent pattern (26). Since GidA mutants produced a
reduced amount of SpeB protein at the time points described
above, it was of interest to determine if the loss of gidA had any
effect on the levels or timing of speB transcription. The growth
FIG. 2. Confirmation of the contribution of gidA to SpeB expression. The integrational plasmids shown at the top were used to disrupt various
regions of the gidA locus in S. pyogenes HSC5. The broken ends of the plasmid-encoded boxes indicate that a gene segment lacks the 5 or 3 end
of the corresponding chromosomal open reading frame, and these regions are indicated by the open boxes above the open reading frames.
Chromosomal structures resulting from the single recombination events (labeled a, b, and c) are indicated below the solid arrow, and the
designations and genotypes of the resulting strains are shown on lines a, b, and c. The open reading frame labeled aad9 encodes a spectinomycin
resistance determinant. The SpeB cysteine protease activities produced by these strains were determined relative to the activity produced by the
wild-type strain (HSC5) (WT) and are indicated in the box on the right. The data are the means and standard errors of the means derived from
at least three independent experiments.
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patterns of the strains (the wild type, the GidA mutant, and
the SPy_2184 mutant) were almost identical (Fig. 4; see Fig. S1
in the supplemental material), so the levels of speB transcript
abundance of the strains at different time points were exam-
ined by real-time RT-PCR. The levels of the speB message in
the wild type exhibited the expected growth phase pattern, with
initiation at the onset of stationary phase and an increase over
the next several hours, followed by a gradual decline (Fig. 4).
The SPy_2184 mutant, which had reduced SpeB activity but
not a reduced level of secreted SpeB protein, exhibited a pat-
tern identical to that of the wild type (Fig. 4). In contrast, the
GidA mutant displayed an aberrant pattern of expression. At
the onset of stationary phase, the abundance of the speB tran-
script was over 60-fold less than that of the wild type (Fig. 4).
The transcript became more abundant over time, until it
reached a level that was not significantly different from the
wild-type level when it was measured in 10-h cultures (Fig. 4).
Disruption of mnmE showed the same phenotype as muta-
tion of gidA. In addition to GidA, modification of U34 in
tRNAs decoding two-family box triplet codons requires addi-
tional enzymes, including MnmE (4, 8, 14, 47). This relation-
ship is supported by the observation that GidA and MnmE
form a heterotetrameric complex in E. coli (47). To examine
whether the SpeB expression defect of GidA mutants was
specific to gidA or was a consequence of the loss of the ability
to modify tRNA, a strain lacking mnmE was constructed (see
Materials and Methods). A Western blot analysis revealed that
the MnmE mutant had a SpeB expression defect identical to
that of the GidA mutant (Fig. 5A), indicating that the entire
pathway for U34 modification may be important for SpeB
biogenesis.
GidA influences SpeB expression via the transcription reg-
ulator RopB. In Shigella flexneri, mutation of several genes
FIG. 3. Reconstitution of disrupted gidA restores SpeB expression.
An intact copy of gidA was inserted into the chromosome of a GidA
mutant (see Materials and Methods for details). (A) Protease produc-
tion on indicator medium. The indicated strains were patched on
protease indicator medium and examined following overnight incuba-
tion. A zone of clearing resulted from protease activity. (B) Quantita-
tive assessment of protease activity. The SpeB cysteine protease activ-
ities in supernatants of 12-h cultures are shown relative to the SpeB
activity of the wild-type strain. The data are the means and standard
errors of the means derived from at least three independent exper-
iments. The following strains were used: wild type (WT), HSC5;
GidA mutant (GidA), HSC5::pKHC100; and GidA comple-
mented (Comp.), HSC5::pKHC100::pKHC103.
FIG. 4. Disruption of gidA results in altered pattern of speB tran-
scription. The relative abundance of the speB message was determined
over the course of growth in several strains using real-time RT-PCR.
For each strain, transcript abundance is shown relative to the abun-
dance of the speB message in the wild-type strain at 6 h. For clarity,
only the growth pattern of the wild-type strain is shown, as the growth
characteristics of all strains were indistinguishable under these condi-
tions (see Fig. S1 in the supplemental material). The transcription data
are the means and standard deviations of three independent experi-
ments. The following strains were used: wild type (WT), HSC5; GidA
mutant (GidA), HSC5::pKHC100; and SPy_2184 mutant (2184),
HSC5::pKHC102. OD600, optical density at 600 nm.
FIG. 5. Overexpression of RopB restores SpeB expression in GidA
pathway mutants. (A) Western blot analysis to detect SpeB in strains
containing a plasmid that overexpresses RopB (pRopB-HA) or in the
absence of a plasmid (no plasmid). Note that multiple proteolytic
cleavages are required for activation of the 46-kDa SpeB zymogen to
the 28-kDa active protease. (B) Western blot analysis to determine the
amount of RopB-HA present in the indicated strains (panel a), with
protein levels quantitated by densitometry and expressed relative to
the wild-type level (line b). Panel c shows the relevant region of the
membrane stained with Coomassie blue for comparison of the
amounts of total protein present in each lane. The following strains
were used: wild type (WT), HSC5; GidA mutant (GidA), HSC5::
pKHC100; and MnmE mutant (MnmE), HSC5::pKHC104.
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involved in tRNA modification results in a reduction in expres-
sion of selected virulence genes as a consequence of poor
translation efficiency of the transcription regulator VirF (13).
Expression of such virulence factors can be rescued in Shigella
mutants by overexpression of VirF (13). In S. pyogenes, tran-
scription of speB is under control of the transcription activator
RopB (26). In the GidA mutant, the abundance of the ropB
transcript was unchanged from the abundance in the wild type
(Fig. 6), suggesting that the tRNA processing mutants may not
efficiently translate this transcription regulator. In this case,
overexpression of RopB should rescue speB expression, similar
to overexpression of VirF in Shigella tRNA modification mu-
tants. To test this, the GidA and MnmE mutants were
transformed with a plasmid that expresses high levels of a
RopB protein that has been modified to include an influenza
HA tag at its carboxy terminus. This construct produces a
functional RopB, as demonstrated by its ability to efficiently
complement a ropB deletion (26). When these transformed
strains were analyzed, it was found that overexpression of
RopB restored the amount of SpeB protein secreted by the
mutants to wild-type levels (Fig. 5A, compare “no plasmid” to
“pRopB-HA”). Even though the amount of RopB that the
mutant strains produced was sufficient to rescue SpeB expres-
sion, these strains produced less than 50% of the amount of
RopB-HA made by the wild-type strain transformed by the
overexpression plasmid (Fig. 5B). These data are consistent
with the idea that the loss of GidA- and MnmE-dependent
tRNA modification alters the pattern of speB transcription via
an effect on the translation efficiency of the ropB message.
Reduced production of multiple secreted virulence proteins.
A sodium dodecyl sulfate-polyacrylamide gel electrophoresis-
based comparison of cytosolic, cell membrane, and cell wall
fractions of GidA and MnmE mutants and the wild type did
not reveal any obvious differences in protein profiles (data not
shown), consistent with the lack of any overall growth defect in
the mutants. Transcription of speB occurs during the early
stationary phase of growth; however, many virulence factors
are expressed in growing cells. Examination of transcription
profiles in growing cells using a microarray analysis indicated
that the loss of GidA had a minimal impact on the global
transcriptome, with only about 2% of the transcripts examined
altered at a level of twofold or greater. Of these, only 0.5%
(seven transcripts) were altered at levels greater than threefold
and none were altered at levels greater than fivefold (see
Tables S2, S3, and S4 in the supplemental material). A lack of
an effect on transcription of virulence-associated genes was
confirmed by a real-time RT-PCR analysis of a subset of mes-
sages, including several messages that encode transcription
regulators implicated in virulence (mga, ropB, and covR) and a
panel of additional factors representing both intracellular and
secreted proteins. This analysis revealed that transcription of
this panel of genes varied only about twofold or less from the
wild-type transcription at 6 h postinoculation (Fig. 6). In con-
trast, examination of the levels of several secreted virulence
proteins, including SPN, SLO, the surface M protein, and MF,
demonstrated that both the GidA and MnmE mutants ex-
pressed each of these proteins at levels that were less than 50%
of the wild-type levels in the exponential phase (Fig. 7). Taken
together, these data suggest that a reduction in expression of
multiple virulence proteins, such as SPN, SLO, M protein, and
MF, in the exponential phase is influenced at the level of
translation by GidA and MnmE and that there may be a
greater impact on virulence factor production than on the
FIG. 6. Nearly normal transcription of multiple virulence factors in
a GidA mutant. The relative levels of abundance of the messages for
the indicated virulence factors in a GidA mutant were determined by
real-time RT-PCR following 6 h of culture in C medium and are
expressed as changes relative to the wild-type strain. Lines indicate
expression that was not different from the wild-type expression (dashed
line) and expression that was twofold different from the wild-type
expression (solid lines). The chromosomal locus and the primers used
for analysis of each gene are listed in Table S1 in the supplemental
material. The transcription data are the means and standard errors of
the means derived from at least two independent experiments. The
following strains were used: wild type, HSC5Spc; and GidA mutant,
HSC5::pKHC100.
FIG. 7. GidA pathway mutants have reduced expression of several
virulence proteins. The results of Western blot analyses to detect the
levels of expression of the indicated virulence proteins in several GidA
pathway mutants are shown. Strains were cultured in THY medium
and harvested at the point of maximal expression of each factor in the
wild-type strain (6 h for SPN, SLO, and M protein; 16 h for MF). A
cysteine protease inhibitor (10 M E64) was added to culture media to
inhibit possible degradation of virulence proteins by SpeB. Expression
levels were determined by densitometry and are expressed relative to
expression in the wild-type strain (indicated below each panel). The
data are the means and standard deviations of two independent ex-
periments. The following strains were used: wild type (WT), HSC5Spc;
GidA mutant (GidA), HSC5::pKHC100; and MnmE mutant
(MnmE), HSC5::pKHC104.
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production of housekeeping proteins that are involved in cell
growth.
Comparison of cytokine profiles from infected macro-
phages. It has been shown that S. pyogenes induces a unique
cytokine activation program in macrophages (21) and that
macrophages have an important role in controlling S. pyogenes
infection in a murine model of disease (20). Since macro-
phages are also a key cell element of the adaptive immune
response, the influence of GidA on streptococcus-macrophage
interaction was assessed. Murine bone marrow-derived mac-
rophages were infected with either the wild type or the GidA
mutant or with these strains following UV treatment to block
growth. After 4 h of infection, supernatant fluids were moni-
tored for the presence of a panel of 23 different cytokines and
chemokines (see Materials and Methods). Overall, the wild
type and the GidA mutant, whether they were UV treated or
not treated, induced identical patterns of expression of 21
cytokines at levels of twofold or greater (Fig. 8; see Fig. S2 in
the supplemental material). The cytokines not stimulated by
both the mutant and the wild type included interleukin 1
(IL-1) and eotaxin (see Fig. S2 in the supplemental material).
For the induced cytokines, the magnitudes of induction were
also similar for the wild type and the GidA mutant (see Fig.
S2 in the supplemental material), with two exceptions. For
both untreated and UV-inactivated cultures, the GidA mu-
tant induced tumor necrosis factor alpha (TNF-) and IL-
12(p40) at levels that were less than 50% of the levels induced
by the wild type (Fig. 8). Since IL-12(p40) is a subunit of both
IL-12 and IL-23 and since the IL-12(p70) subunit of IL-12 was
not differentially expressed (Fig. 8), it was likely that IL-23,
rather IL-12, was differentially induced. This was confirmed by
real-time RT-PCR analysis of the IL-23(p19) subunit, which
showed that this transcript was present in macrophages in-
fected by the GidA mutant at a level that was only 22% 

15% of the level induced in macrophages infected with the wild
type.
GidA mutants are highly attenuated in a murine model of
soft tissue infection. The ability of the GidA mutants to cause
disease in soft tissue was evaluated using the murine subcuta-
neous model. For the strain used in this study (HSC5), injec-
tion into the subcutaneous tissue of an SKH1 hairless mouse
results in a local draining ulcer, whose area reaches the max-
imum value 3 days postinfection and which then goes on to
heal over the next 10 to 14 days (4). In a comparison of the
abilities of a GidA mutant (TM-GidA1) and the wild type to
cause disease in this model, it was found that the latter pro-
duced lesions of the expected size by day 3 postinfection (Fig.
9). In contrast, the GidA mutant was significantly attenuated
in the ability to cause lesions. While a few infected mice ex-
FIG. 8. Cultured macrophages produce reduced levels of TNF-
and IL-12(p40) in response to GidA mutants. The levels of produc-
tion of the indicated cytokines following 4 h of infection of cultured
murine bone marrow-derived macrophages are shown. Cytokine levels
were measured using an antibody-based multiplex bead assay (Bio-
Plex; Bio-Rad Laboratories). Macrophage cultures were infected at a
multiplicity of 10 streptococci per macrophage or were not infected
(Uninfect.). Streptococcal strains were used immediately following
culture (Untreated) or were inactivated by treatment with UV radia-
tion (UV-treated) immediately prior to infection. An asterisk indicates
that expression was significantly decreased compared to the wild type
(P 0.05), and ND indicates that the level of expression was below the
level of detection of the assay. In addition to the expression of IL-
12(p70) shown, there was no difference in expression between the wild
type and the mutant for the 21 other cytokines analyzed in this exper-
iment (see Fig. S2 in the supplemental material). The data are the
means and standard errors of the means from three independent
experiments. The following strains were used: wild type (WT),
HSC5Spc; and GidA mutant (GidA), HSC5::pKHC100.
FIG. 9. GidA mutants are highly attenuated. The ability of a
GidA mutant to cause disease in the murine subcutaneous ulcer
model is shown. Virulence was evaluated on the basis of the area of the
ulcer produced at the time when ulcer formation was maximal in the
wild-type strain (3 days postinfection). The circles and squares repre-
sent ulcer areas in individual mice for the wild type and GidA mutant,
respectively. The solid bars indicate the mean values for the strains,
and P value as determined by a Mann-Whitney U test statistic is
indicated above the bracket. The data shown are pooled data from two
independent experiments. The following strains were used: wild type
(WT), HSC5Spc; and GidA mutant (GidA), HSC5::pKHC100.
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hibited small lesions, the majority of mice infected with the
mutant did not exhibit any visible lesions at day 3 postinfection
or at any subsequent time point. Identical results were ob-
tained with a second GidA mutant (HSC5::pKHC100) (data
not shown). These data indicate that the reduction in virulence
factor expression observed in vitro in the GidA mutants
translates into a severely attenuated ability to cause disease in
soft tissue.
DISCUSSION
This analysis showed that S. pyogenes GidA/MnmE pathway
mutants have a number of characteristics that make them at-
tractive candidates for further evaluation as live vaccine
strains. These characteristics include the fact that they have no
obvious defects in growth, the fact that they have minimal
alterations to the complement of virulence factors that they
produce, the fact that they produce a large subset of these
factors at significantly reduced levels, and the fact that they are
among the most attenuated mutants that have been analyzed
to date using the murine subcutaneous model of soft tissue
infection. Their avirulence appears to be the result of a global
defect in translation efficiency manifested directly on messages
encoding several secreted virulence factors or on messages for
essential regulators of virulence gene transcription. Taken to-
gether, these observations suggest that tRNA modification mu-
tant strains defective in the GidA pathway may be valuable for
probing the mucosal immune response to S. pyogenes.
While the GidA gene was originally isolated as a gene re-
sponsible for a glucose-dependent cell division phenotype in E.
coli (45), more recent studies have established that GidA is a
flavin adenine dinucleotide-dependent enzyme that is required
for addition of the carboxymethylaminomethyl group at posi-
tion 5 of U34 of tRNAs that read mixed codon boxes, including
those for Glu, Gln, Lys, Leu, and Arg (4, 29, 32). Also required
for this modification is the GTPase MnmE, as both GidA and
MnmE mutants of E. coli accumulate the same level of an
undermodified form of U34 (48). This modification restricts
base pairing at the wobble position with C and U to allow
pairing at only G and A residues (63, 64). This prevents both
misincorporation and frameshifting, as GidA and MnmE
mutants have an elevated frequency of a 2 frameshift (4, 7,
29). Prevention of the latter error is likely to have a greater
impact on protein synthesis because while many missense er-
rors can be tolerated in polypeptides, a frameshift generally
produces a truncated nonfunctional protein. Hypomodification
of U34 increases the rate of frameshifting between two- and
fivefold compared with the basal rate in E. coli, depending on
the specific codon (43). If these rates are similar in S. pyogenes,
then this level of frameshifting is well tolerated, as GidA and
MnmE mutants grow at normal rates. However, the obser-
vation that virulence factor expression decreased to levels that
adversely affected pathogenesis suggests that there is more
selective sensitivity of virulence factors than of housekeeping
proteins involved in cell growth.
It is possible that secreted proteins are particularly vulner-
able to U34 hypomodification. The signal sequence required
for protein export includes a positively charged N region and a
hydrophobic H region, which in bacteria are dominated by Lys
and Leu residues, respectively (32), whose codons both require
U34 modifications for efficient decoding. Since many critical
virulence factors of S. pyogenes are secreted proteins, a more
selective defect in expression of these proteins could result in
attenuation of virulence. Alternatively, since many transcrip-
tional regulators have clusters of positively charged Lys and
Arg residues in the domains that they use to bind DNA, they
may be highly sensitive to the loss of GidA and MnmE, since
the codons for these residues require decoding by tRNAs with
U34 modifications. Even a modest decrease in the levels of a
transcription regulator could have a significant pleiotropic ef-
fect on virulence depending on the number target genes that
are dependent on the regulator for their transcription. The
observation that a reduction in the translation efficiency of the
ropB message is at least one factor contributing to the disregu-
lation of expression of the SpeB protease illustrates the vul-
nerability of transcription regulators to alterations in the level
of modified tRNAs. The ska gene was slightly overexpressed in
the transcript analysis (Fig. 6), and this might indicate that less
of a repressor of ska is produced translationally in the GidA
mutant. Similarly, it has been shown that mutations that alter
levels of U34 and A37 tRNA modification attenuate the viru-
lence of S. flexneri exclusively via a decrease in the translation
efficiency of the gene encoding the VirF transcription activator
(13). It has been proposed that tRNA modification can func-
tion as a regulatory mechanism to adjust gene expression in
response to nutrient deprivation via alterations in pools of
cofactors required for the tRNA modification reactions (35).
Whether the levels of VirF in S. flexneri or RopB is regulated
by this mechanism remains to be determined.
In addition to mutants of S. pyogenes and S. flexneri, tRNA
modification mutants of other pathogens have been shown to
have robust defects in virulence in the absence of any remark-
able defects in growth. For example, defects in virulence
and/or virulence factor production associated with defects in
tRNA modification have been reported for Agrobacterium tu-
mefaciens (23), Pseudomonas syringae (24), and Aeromonas
hydrophila (39). Prominent phenotypes for tRNA modification
mutants have also been reported both for nonpathogenic bac-
teria and for eukaryotic pathogens, including Myxococcus xan-
thus (46) and the phytopathogenic fungus Colletotrichum
lagenarium (42). The observation that tRNA mutants are fre-
quently attenuated, combined with the fact that tRNA modi-
fication is a universal feature of all living cells, suggests that
mutation of tRNA modification genes may prove to be a gen-
eral strategy for construction of live attenuated vaccine strains.
Since analysis of mucosal immunity against several other
pathogenic streptococcal species, including Streptococcus aga-
lactiae and Streptococcus pneumoniae, could benefit from the
availability of live attenuated strains, it will be of interest to
evaluate virulence factor expression and pathogenesis of
GidA and MnmE mutants of these species.
Another characteristic that should make the S. pyogenes
tRNA modification mutants useful as live attenuated strains is
the fact that they do not have a major defect in the number of
different virulence factors that they can express relative to the
wild type. This suggests that they can engage the adaptive
immune system in a manner similar to the manner of the wild
type. This idea is supported by the observation that macro-
phages respond to the mutant and the wild type in similar ways,
as revealed by the nearly identical cytokine profiles observed.
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The mutants did stimulate several cytokines to a lesser extent
than the wild type, most notably TNF-. Macrophage-derived
TNF- is an important early mediator of the inflammatory
cascade, and it is known that S. pyogenes infection stimulates
production of TNF- in murine (26, 59) and baboon (41)
models of infection and in human patients with severe invasive
disease (33). However, in both humans and baboons, high
levels of TNF- were correlated with more serious disease (44,
54), suggesting that overproduction of TNF- contributes to
pathogenesis. Consistent with this, treatment of septic baboons
with an anti-TNF- monoclonal antibody markedly improved
both symptoms and survival (41). Thus, the reduced ability of
tRNA modification mutants to stimulate TNF- may prove to
be a useful property for a live attenuated strain.
It is less clear whether the attenuated strains will be useful
for vaccination of human populations. Possible complications
include the fact that the attenuated strains may also express
epitopes that contribute to autoimmune sequlae and the fact
that they express only a single serotype of the highly variant M
protein molecule. It may be possible to engineer the attenu-
ated strains to produce altered M protein variants lacking
known cross-reactive epitopes and to express M protein do-
mains common to multiple serotypes. Regardless, the avail-
ability of live attenuated strains, like the tRNA mutants de-
scribed in this work, should be a valuable resource for further
vaccine development.
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